

AMENDMENTS TO THE CLAIMS

1. (Original) An isolated T cell expressing a T cell receptor specific for an MHC-peptide complex comprising a first housekeeping epitope, wherein the housekeeping epitope is derived from a first antigen associated with a first target cell.

2. (Original) A T cell clone comprising the T cell of claim 1.

3. (Original) A polyclonal population of T cells comprising the T cell of claim 1.

4. (Original) The T cell of claim 1 produced by an in vitro immunization.

5. (Original) The T cell of claim 1 isolated from an immunized animal.

6-28 (Cancelled)

29. (New) The isolated T cell of Claim 1, wherein the first target cell is a neoplastic cell.

30. (New) The isolated T cell of Claim 1, wherein the first antigen is a tumor associated antigen.

31. (New) The isolated T cell of Claim 30, wherein the tumor associated antigen is a cancer-testis antigen.

32. (New) The isolated T cell of Claim 30, wherein the tumor associated antigen is selected from the group consisting of NY-ESO, PSMA, SSX-2 and PRAME.

33. (New) The isolated T cell of Claim 30, wherein the tumor associated antigen is a melanoma differentiation antigen.

34. (New) The isolated T cell of Claim 33, wherein the melanoma differentiation antigen is selected from the group consisting of tyrosinase, MelanA, and gp100.

35. (New) The isolated T cell of Claim 1, wherein the MHC is A2.

36. (New) The isolated T cell of Claim 1, wherein the MHC is selected from the group consisting of A1, A3, A24, B7 and B8.